In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients

被引:0
|
作者
Tomasz Olszak
Paulina Zarnowiec
Wieslaw Kaca
Katarzyna Danis-Wlodarczyk
Daria Augustyniak
Pavel Drevinek
Anthony de Soyza
Siobhán McClean
Zuzanna Drulis-Kawa
机构
[1] University of Wroclaw,Institute of Genetics and Microbiology
[2] The Jan Kochanowski University,Division of Gene Technology
[3] Catholic University of Leuven,Department of Medical Microbiology, University Hospital Motol and 2nd Faculty of Medicine
[4] Charles University,Institute of Cellular Medicine, Medical School
[5] Newcastle University,Centre of Microbial Host Interactions
[6] Institute of Technology Tallaght,undefined
来源
Applied Microbiology and Biotechnology | 2015年 / 99卷
关键词
bacteriophages; Phage treatment; Cystic fibrosis; model;
D O I
暂无
中图分类号
学科分类号
摘要
The goal of the study was to determine the relationship between in vitro/in vivo efficacy of environmental Pseudomonas phages and certain phenotypical properties of Pseudomonas aeruginosa (PA) strains. We studied the diversity between particular isolates and determined phage sensitivity in vitro and in vivo in the Galleria mellonella insect model. Twenty-eight lytic bacteriophages specific for PA were tested against 121 CF PA isolates including 29 mucoid PA strains. Most strains from cystic fibrosis (CF) patients were lysed by at least three phages (93.6 %), but completely insensitive strains were also present (6.4 %). Two phages PA5oct and KT28 exhibited high rates of lytic potency on 55–68 % of PA strains (72–86 % of mucoid isolates). We further explored phage activity against six PA strains (CF and non-CF) in vitro, comparing clonal differences in phage susceptibility with bacterial properties such as the ability to form biofilms, mucosity, twitching motility, and biochemical profiles. We observed the relationship between variation in phage susceptibility and Fourier transform infrared spectroscopy (FTIR) analysis in the spectra window of carbohydrates. The protective efficacy of two selected phages against PA PAO1 and 0038 infection was confirmed in vivo in G. mellonella larvae. Generally, the wax moth model results confirmed the data from in vitro assays, but in massive infection of CF isolates, the application of lytic phages probably led to the release of toxic compound causing an increase in larvae mortality. We assumed that apart of in vitro phage activity testing, a simple and convenient wax moth larvae model should be applied for the evaluation of in vivo effectiveness of particular phage preparations.
引用
收藏
页码:6021 / 6033
页数:12
相关论文
共 50 条
  • [41] Isolation, Characterization, and Genomic Analysis of Bacteriophages Against Pseudomonas aeruginosa Clinical Isolates from Early and Chronic Cystic Fibrosis Patients for Potential Phage Therapy
    El-Din, Hanzada T. Nour
    Kettal, Maryam
    Maciel, Jose C. Granados
    Beaudoin, Greg
    Oktay, Umut
    Hrapovic, Sabahudin
    Sad, Subash
    Dennis, Jonathan J.
    Peters, Danielle L.
    Chen, Wangxue
    MICROORGANISMS, 2025, 13 (03)
  • [42] In vitro Activities of the Novel Ceragenin CSA-13, Alone or in Combination with Colistin, Tobramycin, and Ciprofloxacin, against Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients
    Bozkurt-Guzel, Cagla
    Savage, Paul B.
    Gerceker, Ayse Alev
    CHEMOTHERAPY, 2011, 57 (06) : 505 - 510
  • [43] Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
    Murphy, Ronan A.
    Coates, Matthew
    Thrane, Sophia
    Sabnis, Akshay
    Harrison, James
    Schelenz, Silke
    Edwards, Andrew M.
    Vorup-Jensen, Thomas
    Davies, Jane C.
    MICROBIOLOGY SPECTRUM, 2022, 10 (04):
  • [44] Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis
    J. Manos
    H. Hu
    B. R. Rose
    C. E. Wainwright
    I. B. Zablotska
    J. Cheney
    L. Turnbull
    C. B. Whitchurch
    K. Grimwood
    C. Harmer
    S. N. Anuj
    C. Harbour
    European Journal of Clinical Microbiology & Infectious Diseases, 2013, 32 : 1583 - 1592
  • [45] Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: I nfluence of the Culture Medium
    Iglesias, Yvan Diaz
    Van Bambeke, Francoise
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (04)
  • [46] In vitro Activity of Antivirulence Drugs Targeting the las or pqs Quorum Sensing Against Cystic Fibrosis Pseudomonas aeruginosa Isolates
    Collalto, Diletta
    Giallonardi, Giulia
    Fortuna, Alessandra
    Meneghini, Carlo
    Fiscarelli, Ersilia
    Visca, Paolo
    Imperi, Francesco
    Rampioni, Giordano
    Leoni, Livia
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [47] Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model
    Craddock, Vaughn D.
    Steere, Evan L.
    Harman, Hannah
    Britt, Nicholas S.
    ANTIBIOTICS-BASEL, 2023, 12 (06):
  • [48] Phenotypic and genotypic characterization of Pseudomonas aeruginosa from cystic fibrosis patients
    I. Leone
    M. G. Chirillo
    T. Raso
    M. Zucca
    D. Savoia
    European Journal of Clinical Microbiology & Infectious Diseases, 2008, 27
  • [49] Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review
    Ratjen, Felix
    Brockhaus, Florian
    Angyalosi, Gerhild
    JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (06) : 361 - 369
  • [50] Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis
    Jose Martinez-Gallardo, Maria
    Villicana, Claudia
    Yocupicio-Monroy, Martha
    Lizeth Alcaraz-Estrada, Sofia
    Leon-Felix, Josefina
    FOLIA MICROBIOLOGICA, 2023, 68 (01) : 1 - 16